Transmedics Group (TMDX) reported $605M in revenue for fiscal 2025, +37.1% year on year. That ranks #2101 by revenue among 2853 SEC filers and #202 in Healthcare. Net income was $190M, a net margin of 31.4%. Revenue has grown 70.2% a year on average since 2018 ($14.7M then). The fiscal 2025 balance sheet shows $1.1B in total assets, $489M in cash and $58.7M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $605M | +37.1% | FY20252025-12-31 |
| Gross profitGrossProfit | $363M | +38.4% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $109M | +189.6% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $190M | +436.1% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $193M | +295.1% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $59.3M | −54.3% | FY20252025-12-31 |
| Total assetsAssets | $1.1B | +32.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $473M | +107.0% | FY20252025-12-31 |
| CashCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $489M | +45.0% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $58.7M | +66.8% | FY20222022-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $174M | $7.3M | Open → |
| Q2 20262026-06-30 | $190M | $14.7M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Transmedics Group, Inc.
- Ticker
- TMDX
- Exchange
- Nasdaq
- SIC classification
- Electromedical & Electrotherapeutic Apparatus (3845)
- Fiscal year end
- 12-31
- CIK
- 0001756262
Filings
- 10-QAug 4, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KFeb 24, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Cadre HoldingsCDRE | $610M | $44.1M |
| Opko HealthOPK | $607M | −$226M |
| InsmedINSM | $606M | −$1.3B |
| Transmedics GroupTMDX | $605M | $190M |
| Ufp TechnologiesUFPT | $603M | $68.3M |
| Catalyst PharmaceuticalsCPRX | $589M | $214M |
| AlvotechALVO | $586M | $27.9M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Transmedics Group — Key figures |url=https://companiesranked.com/en/company/transmedics-group |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Transmedics Group — Key figures. CompaniesRanked. https://companiesranked.com/en/company/transmedics-groupBibTeX
@misc{companiesranked-en-company-transmedics-group-2026,
author = {{CompaniesRanked}},
title = {{Transmedics Group — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/transmedics-group}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-067032 · February 24, 2026
{{cite web |title=Transmedics Group — Key figures — 10-K (0001193125-26-067032) |url=https://www.sec.gov/Archives/edgar/data/1756262/000119312526067032/tmdx-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.